CDXS
NASDAQ
US
Codexis, Inc. - Common Stock
$1,82
▲ +$0,08
(+4,60%)
Vol 778K
3
Skor Kualitas
fail
Pendapatan ✗
Laba Bersih ✗
>IPO ✗
Kap. Pasar
$147.2M
ROE
-121,4%
Margin
-120,8%
D/E
103,07
Beta
2,47
52W
$2–$6
Konsensus Wall Street
13 analis · Apr 20264
Beli Kuat
6
Beli
3
Tahan
0
Jual
0
Jual Kuat
76,9%
Peringkat Beli
Grafik Harga
Saham Serupa
OABI
OmniAb Inc
$266.3M
ATLN
Atlantic International Corp
$77.8M
QTRX
Quanterix Corp
$297.1M
TKNO
Alpha Teknova Inc
$203.4M
QSI
Quantum-Si Inc
$237.0M
LFCR
Lifecore Biomedical Inc
$306.5M
SEER
Seer Inc
$102.1M
RPID
Rapid Micro Biosystems Inc
$128.5M
CSBR
Champions Oncology Inc
P/E 32,5
$96.0M
MXCT
MaxCyte Inc
$165.3M
Pendapatan
Tingkat beat: 40,0%| Kuartal | EPS Estimasi | EPS Aktual | Kejutan |
|---|---|---|---|
| Des 2025 | $-0,04 | $0,11 | +$0,15 |
| Sep 2025 | $-0,15 | $-0,22 | $-0,07 |
| Jun 2025 | $-0,19 | $-0,16 | +$0,03 |
| Mar 2025 | $-0,24 | $-0,25 | $-0,01 |
Pendapatan & Laba Kuartalan
| Kuartal | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Pendapatan | — | $21.5M | $7.5M | $15.3M | $8.6M | $38.9M |
| Laba Bersih | — | -$10.4M | -$20.7M | -$13.3M | -$19.6M | $9.6M |
Tren Fundamental
| Metrik | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -105.8% | -118.5% | -105.8% | -105.8% | -121.4% | -121.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -86.6% | -149.5% | -113.7% | -113.7% | -120.8% | -120.8% |
| Gross Margin | 86.3% | 71.6% | 77.6% | 77.6% | 79.3% | 79.3% |
| D/E Ratio | 70.78 | 58.81 | 70.78 | 70.78 | 103.07 | 103.07 |
| Current Ratio | 5.82 | 3.72 | 5.82 | 5.82 | 4.12 | 4.12 |
Rasio Utama
ROA (TTM)
-47,4%
P/S (TTM)
2,78
P/B
5,8
EPS (TTM)
$-0,75
CF/Share
$-1,13
Pertumbuhan Pendapatan 3T
-17,3%
52W High
$5,51
52W Low
$1,52
$1,52
Rentang 52 Minggu
$5,51
Kesehatan Keuangan
Arus Kas Bebas
$19.6M
Utang Bersih
$22.4M
Kas
$50.8M
Total Utang
$73.2M
Per tanggal Des 31, 2025
Як CDXS виглядає на тлі конкурентів у Life Sciences Tools & Services?
Група порівняння: Micro-cap Life Sciences Tools & Services (All) · 44 компаній
Оцінка CDXS vs аналоги Life Sciences Tools & Services
P/E
—
▼
0%
di bawah
rekan
(32,5)
vs Rekan
vs Industri
Undervalued
P/S
2,8
▼
26%
di bawah
rekan
(3,7)
vs Rekan
vs Industri
Lebih mahal
P/B
5,8
▲
194%
di atas
rekan
(2,0)
vs Rekan
vs Industri
Overvalued
Дивідендна дохідність
—
▼
0%
di bawah
rekan
(0,5%)
vs Rekan
vs Industri
Yield rendah
Прибутковість CDXS vs аналоги Life Sciences Tools & Services
ROE
-121,4%
▼
392%
di bawah
rekan
(-24,7%)
vs Rekan
vs Industri
Lemah
Net margin
-120,8%
▼
334%
di bawah
rekan
(-27,8%)
vs Rekan
vs Industri
Lemah
Валова маржа
79,3%
▲
64%
di atas
rekan
(48,2%)
vs Rekan
vs Industri
Tingkat atas
ROA
-47,4%
▼
225%
di bawah
rekan
(-14,6%)
vs Rekan
vs Industri
Lemah
Фінансове здоровʼя CDXS vs аналоги Life Sciences Tools & Services
D/E ratio
103,1
▲
345%
di atas
rekan
(23,2)
vs Rekan
vs Industri
Utang tinggi
Поточна ліквідність
4,1
▲
24%
di atas
rekan
(3,3)
vs Rekan
vs Industri
Di bawah rata-rata
Beta
2,5
▲
79%
di atas
rekan
(1,4)
vs Rekan
vs Industri
Lebih volatil
Радар фундаменталів CDXS
CDXS
Median rekan
Industri
CDXS прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CDXS vs аналоги: ключові метрики
Aktivitas Orang Dalam
NeutralPembelian
0
Penjualan
0
LUTZ STEFAN
Officer · Feb 24
5862 shs
ERBEZ GEORGIA L
Chief Financial Officer · Feb 06
3826 shs
MOORE ALISON
Chief Executive Officer · Feb 06
3826 shs
LUTZ STEFAN
Officer · Feb 06
2492 shs
LUTZ STEFAN
Officer · Jan 07
4685 shs
Terakhir 90 hari
Pemegang Terbesar
Top 5: 34,21%Aberdeen Group plc
8,77%
$12.6M
Blackrock Inc.
8,14%
$11.7M
Opaleye Management Inc.
7,47%
$10.7M
Vanguard Group Inc
5,44%
$7.8M
Nantahala Capital Managemen…
4,39%
$6.3M
Per tanggal Des 31, 2025
Berita Terbaru
Belum ada berita terkait